secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2026-06-16T12:39:37+00:00
Accession:  0001628280-26-043431
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeneDx names Mark Gardner as President, effective June 15, 2026
---------------------------------------------------------------

- Mr. Gardner, former Quest Diagnostics SVP, will oversee lab and commercial ops, reporting to CEO Katherine Stueland.
- Compensation includes $530K base salary, 65% target bonus, and $2M RSU grant vesting over four years.
- Bryan Dechairo transitions to lead product, technology and innovation initiatives.
- Gardner previously served as CEO of OmniSeq and held senior roles at Thermo Fisher Scientific and Life Technologies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000162828026043431/0001628280-26-043431-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000162828026043431/wgs-20260615.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-043431

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer